These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 36555145)
1. Fecal Luminal Factors from Patients with Gastrointestinal Diseases Alter Gene Expression Profiles in Caco-2 Cells and Colonoids. Holst LM; Iribarren C; Sapnara M; Savolainen O; Törnblom H; Wettergren Y; Strid H; Simrén M; Magnusson MK; Öhman L Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555145 [TBL] [Abstract][Full Text] [Related]
2. Fecal luminal factors from patients with irritable bowel syndrome induce distinct gene expression of colonoids. Iribarren C; Nordlander S; Sundin J; Isaksson S; Savolainen O; Törnblom H; Magnusson MK; Simrén M; Öhman L Neurogastroenterol Motil; 2022 Oct; 34(10):e14390. PubMed ID: 35485994 [TBL] [Abstract][Full Text] [Related]
3. Exposure of Colon-Derived Epithelial Monolayers to Fecal Luminal Factors from Patients with Colon Cancer and Ulcerative Colitis Results in Distinct Gene Expression Patterns. Magnusson MK; Bas Forsberg A; Verveda A; Sapnara M; Lorent J; Savolainen O; Wettergren Y; Strid H; Simrén M; Öhman L Int J Mol Sci; 2024 Sep; 25(18):. PubMed ID: 39337373 [TBL] [Abstract][Full Text] [Related]
4. Lactobacillus rhamnosus GG prevents epithelial barrier dysfunction induced by interferon-gamma and fecal supernatants from irritable bowel syndrome patients in human intestinal enteroids and colonoids. Han X; Lee A; Huang S; Gao J; Spence JR; Owyang C Gut Microbes; 2019; 10(1):59-76. PubMed ID: 30040527 [TBL] [Abstract][Full Text] [Related]
5. Fecal proteases from diarrheic-IBS and ulcerative colitis patients exert opposite effect on visceral sensitivity in mice. Annaházi A; Gecse K; Dabek M; Ait-Belgnaoui A; Rosztóczy A; Róka R; Molnár T; Theodorou V; Wittmann T; Bueno L; Eutamene H Pain; 2009 Jul; 144(1-2):209-17. PubMed ID: 19450926 [TBL] [Abstract][Full Text] [Related]
6. Impaired Luminal Control of Intestinal Macrophage Maturation in Patients With Ulcerative Colitis During Remission. Maasfeh L; Härtlova A; Isaksson S; Sundin J; Mavroudis G; Savolainen O; Strid H; Öhman L; Magnusson MK Cell Mol Gastroenterol Hepatol; 2021; 12(4):1415-1432. PubMed ID: 34126236 [TBL] [Abstract][Full Text] [Related]
7. Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome. Langhorst J; Junge A; Rueffer A; Wehkamp J; Foell D; Michalsen A; Musial F; Dobos GJ Am J Gastroenterol; 2009 Feb; 104(2):404-10. PubMed ID: 19174795 [TBL] [Abstract][Full Text] [Related]
8. The Promise of Patient-Derived Colon Organoids to Model Ulcerative Colitis. Ojo BA; VanDussen KL; Rosen MJ Inflamm Bowel Dis; 2022 Feb; 28(2):299-308. PubMed ID: 34251431 [TBL] [Abstract][Full Text] [Related]
9. Interferon-γ is increased in the gut of patients with irritable bowel syndrome and modulates serotonin metabolism. Barbaro MR; Di Sabatino A; Cremon C; Giuffrida P; Fiorentino M; Altimari A; Bellacosa L; Stanghellini V; Barbara G Am J Physiol Gastrointest Liver Physiol; 2016 Mar; 310(6):G439-47. PubMed ID: 26744473 [TBL] [Abstract][Full Text] [Related]
10. Metabolomics of fecal extracts detects altered metabolic activity of gut microbiota in ulcerative colitis and irritable bowel syndrome. Le Gall G; Noor SO; Ridgway K; Scovell L; Jamieson C; Johnson IT; Colquhoun IJ; Kemsley EK; Narbad A J Proteome Res; 2011 Sep; 10(9):4208-18. PubMed ID: 21761941 [TBL] [Abstract][Full Text] [Related]
11. Luminal cathepsin g and protease-activated receptor 4: a duet involved in alterations of the colonic epithelial barrier in ulcerative colitis. Dabek M; Ferrier L; Roka R; Gecse K; Annahazi A; Moreau J; Escourrou J; Cartier C; Chaumaz G; Leveque M; Ait-Belgnaoui A; Wittmann T; Theodorou V; Bueno L Am J Pathol; 2009 Jul; 175(1):207-14. PubMed ID: 19528350 [TBL] [Abstract][Full Text] [Related]
12. Protease signaling through protease activated receptor 1 mediate nerve activation by mucosal supernatants from irritable bowel syndrome but not from ulcerative colitis patients. Buhner S; Hahne H; Hartwig K; Li Q; Vignali S; Ostertag D; Meng C; Hörmannsperger G; Braak B; Pehl C; Frieling T; Barbara G; De Giorgio R; Demir IE; Ceyhan GO; Zeller F; Boeckxstaens G; Haller D; Kuster B; Schemann M PLoS One; 2018; 13(3):e0193943. PubMed ID: 29529042 [TBL] [Abstract][Full Text] [Related]
13. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Piche T; Barbara G; Aubert P; Bruley des Varannes S; Dainese R; Nano JL; Cremon C; Stanghellini V; De Giorgio R; Galmiche JP; Neunlist M Gut; 2009 Feb; 58(2):196-201. PubMed ID: 18824556 [TBL] [Abstract][Full Text] [Related]
14. Gut microbiota in mucosa and feces of newly diagnosed, treatment-naïve adult inflammatory bowel disease and irritable bowel syndrome patients. Čipčić Paljetak H; Barešić A; Panek M; Perić M; Matijašić M; Lojkić I; Barišić A; Vranešić Bender D; Ljubas Kelečić D; Brinar M; Kalauz M; Miličević M; Grgić D; Turk N; Karas I; Čuković-Čavka S; Krznarić Ž; Verbanac D Gut Microbes; 2022; 14(1):2083419. PubMed ID: 35695669 [TBL] [Abstract][Full Text] [Related]
15. Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation. Vivinus-Nébot M; Frin-Mathy G; Bzioueche H; Dainese R; Bernard G; Anty R; Filippi J; Saint-Paul MC; Tulic MK; Verhasselt V; Hébuterne X; Piche T Gut; 2014 May; 63(5):744-52. PubMed ID: 23878165 [TBL] [Abstract][Full Text] [Related]